Medindia

X

Ardea Biosciences to Present at Roth Capital Partners' 20th Annual OC Growth Stock Conference

Wednesday, February 13, 2008 General News J E 4
Advertisement
CARLSBAD, Calif., Feb. 12 Ardea Biosciences,Inc. (Nasdaq: RDEA) today announced that Barry D. Quart, PharmD, President andCEO of Ardea Biosciences, will present at the Roth Capital Partners' 20thAnnual OC Growth Stock Conference.

About Ardea Biosciences, Inc.

Ardea Biosciences of Carlsbad, California is a biotechnology companyfocused on the discovery and development of small-molecule therapeutics invirology, oncology and inflammation. The Company has two product candidates inclinical development and several others in preclinical development. Ardea'smost advanced clinical development candidate is RDEA806, a non-nucleosidereverse transcriptase inhibitor (NNRTI), which is in a Phase 2a study for thetreatment of HIV. In addition, the Company is also investigating RDEA806 forthe treatment of gout. In oncology, the Company is investigating amitogen-activated ERK kinase (MEK) inhibitor, RDEA119, in a Phase 1 study inadvanced cancer patients. Ardea also is developing a next-generation NNRTI forHIV and a next-generation MEK inhibitor for both cancer and inflammatorydiseases.

Statements contained in this press release regarding matters that are nothistorical facts are "forward-looking statements" within the meaning of thePrivate Securities Litigation Reform Act of 1995. Because such statements aresubject to risks and uncertainties, actual results may differ materially fromthose expressed or implied by such forward-looking statements. Such statementsinclude, but are not limited to, statements regarding: Ardea's goals,including the expected properties and benefits of RDEA806, RDEA119 and itsother compounds and the results of clinical and other studies. Risks thatcontribute to the uncertain nature of the forward-looking statements include:risks related to the outcomes of preclinical and clinical trials, risksrelated to regulatory approvals, delays in commencement of preclinical andclinical tests, and costs associated with internal development andin-licensing activities. These and other risks and uncertainties are describedmore fully in Ardea's most recently filed SEC documents, including its AnnualReport on Form 10-K and Quarterly Reports on Form 10-Q, under the headings"Risk Factors." All forward-looking statements contained in this press releasespeak only as of the date on which they were made. Ardea undertakes noobligation to update such statements to reflect events that occur orcircumstances that exist after the date on which they were made.Date: Tuesday, February 19, 2008 Time: 4:00 p.m. Pacific Time Location: The Ritz Carlton Laguna Niguel, Dana Point, CA Webcast: http://www.wsw.com/webcast/roth16/rdea/ or http://www.ardeabio.com

SOURCE Ardea Biosciences, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
WaferGen to Present at the Roth Capital Partners 2...
S
Natural Alternatives International, Inc. Appoints ...